Dr. Robert Holloway, MD
Claim this profileAdventHealth Cancer Institute
Studies Ovarian Cancer
Studies Ovarian Tumors
11 reported clinical trials
23 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
Stage III
2Ovarian Tumors
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Robert Holloway, MD is currently running
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
Alpelisib + Fulvestrant
for Endometrial Cancer
This trial tests a combination of two drugs, alpelisib and fulvestrant, in patients with a specific type of endometrial cancer. These patients have a genetic mutation (PIK3CA) and their cancer grows in response to estrogen. Alpelisib targets the mutation, while fulvestrant blocks estrogen, aiming to stop cancer growth. Alpelisib is the first drug of its kind approved for use with fulvestrant based on its effectiveness in treating similar types of cancer.
Recruiting1 award Phase 210 criteria
More about Robert Holloway, MD
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Robert Holloway, MD has experience with
- Carboplatin
- Paclitaxel
- Defactinib
- Olvimulogene Nanivacirepvec
- Gemcitabine
- Bevacizumab
Breakdown of trials Robert Holloway, MD has run
Ovarian Cancer
Ovarian Tumors
Fallopian Tube Cancer
Peritoneal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Holloway, MD specialize in?
Robert Holloway, MD focuses on Ovarian Cancer and Ovarian Tumors. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Robert Holloway, MD currently recruiting for clinical trials?
Yes, Robert Holloway, MD is currently recruiting for 3 clinical trials in Orlando Florida. If you're interested in participating, you should apply.
Are there any treatments that Robert Holloway, MD has studied deeply?
Yes, Robert Holloway, MD has studied treatments such as Carboplatin, Paclitaxel, Defactinib.
What is the best way to schedule an appointment with Robert Holloway, MD?
Apply for one of the trials that Robert Holloway, MD is conducting.
What is the office address of Robert Holloway, MD?
The office of Robert Holloway, MD is located at: AdventHealth Cancer Institute, Orlando, Florida 32804 United States. This is the address for their practice at the AdventHealth Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.